Cargando…

Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate

The family members of Arenaviridae include members of the genus Machupo virus, which have bi-segmented negative sense RNA inside the envelope and can be transferred to humans through rodent carriers. Machupo virus, a member of the mammarenavirus genus, causes Bolivian hemorrhage fever, its viral nuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Naveed, Muhammad, Makhdoom, Syeda Izma, Ali, Urooj, Jabeen, Khizra, Aziz, Tariq, Khan, Ayaz Ali, Jamil, Sumbal, Shahzad, Muhammad, Alharbi, Metab, Alshammari, Abdulrahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609340/
https://www.ncbi.nlm.nih.gov/pubmed/36298597
http://dx.doi.org/10.3390/vaccines10101732
_version_ 1784818994563252224
author Naveed, Muhammad
Makhdoom, Syeda Izma
Ali, Urooj
Jabeen, Khizra
Aziz, Tariq
Khan, Ayaz Ali
Jamil, Sumbal
Shahzad, Muhammad
Alharbi, Metab
Alshammari, Abdulrahman
author_facet Naveed, Muhammad
Makhdoom, Syeda Izma
Ali, Urooj
Jabeen, Khizra
Aziz, Tariq
Khan, Ayaz Ali
Jamil, Sumbal
Shahzad, Muhammad
Alharbi, Metab
Alshammari, Abdulrahman
author_sort Naveed, Muhammad
collection PubMed
description The family members of Arenaviridae include members of the genus Machupo virus, which have bi-segmented negative sense RNA inside the envelope and can be transferred to humans through rodent carriers. Machupo virus, a member of the mammarenavirus genus, causes Bolivian hemorrhage fever, its viral nucleocapsid protein being a significant virulence factor. Currently, no treatment is available for Bolivian hemorrhage fever and work to develop a protective as well as post-diagnosis treatment is underway. Adding to these efforts, this study employed a reverse-vaccinology approach to design a vaccine with B and T-cell epitopes of the viral nucleocapsid protein of the Machupo virus. Five B-cell specific, eight MHC-I restricted, and 14 MHC-II restricted epitopes were finalized for the construct based on an antigenicity score of >0.5 and non-allergenicity as a key characteristic. The poly-histidine tag was used to construct an immunogenic and stable vaccine construct and 50S ribosomal 46 protein L7/L12 adjuvant with linkers (EAAAK, GPGPG, and AYY). It covers 99.99% of the world’s population, making it highly efficient. The physicochemical properties like the aliphatic index (118.31) and the GRAVY index (0.302) showed that the vaccine is easily soluble. The overall Ramachandran score of the construct was 90.7%, and the instability index was 35.13, endorsing a stable structure. The immune simulations demonstrated a long-lasting antibody response even after the excretion of the antigen from the body in the first 5 days of injection. The IgM + IgG titers were predicted to rise to 6000 10 days post-injection and were illustrated to be stable (around 3000) after a month, elucidating that the vaccine would be effective and provide enduring protection. Lastly, the molecular interaction between the construct and the IKBKE receptor was significant and a higher eigenfactor value in MD simulations confirmed the stable molecular interaction between the receptor and the vaccine, validating our construct.
format Online
Article
Text
id pubmed-9609340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96093402022-10-28 Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate Naveed, Muhammad Makhdoom, Syeda Izma Ali, Urooj Jabeen, Khizra Aziz, Tariq Khan, Ayaz Ali Jamil, Sumbal Shahzad, Muhammad Alharbi, Metab Alshammari, Abdulrahman Vaccines (Basel) Article The family members of Arenaviridae include members of the genus Machupo virus, which have bi-segmented negative sense RNA inside the envelope and can be transferred to humans through rodent carriers. Machupo virus, a member of the mammarenavirus genus, causes Bolivian hemorrhage fever, its viral nucleocapsid protein being a significant virulence factor. Currently, no treatment is available for Bolivian hemorrhage fever and work to develop a protective as well as post-diagnosis treatment is underway. Adding to these efforts, this study employed a reverse-vaccinology approach to design a vaccine with B and T-cell epitopes of the viral nucleocapsid protein of the Machupo virus. Five B-cell specific, eight MHC-I restricted, and 14 MHC-II restricted epitopes were finalized for the construct based on an antigenicity score of >0.5 and non-allergenicity as a key characteristic. The poly-histidine tag was used to construct an immunogenic and stable vaccine construct and 50S ribosomal 46 protein L7/L12 adjuvant with linkers (EAAAK, GPGPG, and AYY). It covers 99.99% of the world’s population, making it highly efficient. The physicochemical properties like the aliphatic index (118.31) and the GRAVY index (0.302) showed that the vaccine is easily soluble. The overall Ramachandran score of the construct was 90.7%, and the instability index was 35.13, endorsing a stable structure. The immune simulations demonstrated a long-lasting antibody response even after the excretion of the antigen from the body in the first 5 days of injection. The IgM + IgG titers were predicted to rise to 6000 10 days post-injection and were illustrated to be stable (around 3000) after a month, elucidating that the vaccine would be effective and provide enduring protection. Lastly, the molecular interaction between the construct and the IKBKE receptor was significant and a higher eigenfactor value in MD simulations confirmed the stable molecular interaction between the receptor and the vaccine, validating our construct. MDPI 2022-10-17 /pmc/articles/PMC9609340/ /pubmed/36298597 http://dx.doi.org/10.3390/vaccines10101732 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naveed, Muhammad
Makhdoom, Syeda Izma
Ali, Urooj
Jabeen, Khizra
Aziz, Tariq
Khan, Ayaz Ali
Jamil, Sumbal
Shahzad, Muhammad
Alharbi, Metab
Alshammari, Abdulrahman
Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title_full Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title_fullStr Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title_full_unstemmed Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title_short Immunoinformatics Approach to Design Multi-Epitope-Based Vaccine against Machupo Virus Taking Viral Nucleocapsid as a Potential Candidate
title_sort immunoinformatics approach to design multi-epitope-based vaccine against machupo virus taking viral nucleocapsid as a potential candidate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609340/
https://www.ncbi.nlm.nih.gov/pubmed/36298597
http://dx.doi.org/10.3390/vaccines10101732
work_keys_str_mv AT naveedmuhammad immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT makhdoomsyedaizma immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT aliurooj immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT jabeenkhizra immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT aziztariq immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT khanayazali immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT jamilsumbal immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT shahzadmuhammad immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT alharbimetab immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate
AT alshammariabdulrahman immunoinformaticsapproachtodesignmultiepitopebasedvaccineagainstmachupovirustakingviralnucleocapsidasapotentialcandidate